Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease of the prostaglandin I2 binding capacity in thyroids from patients with Graves' disease.

I Virgolini1, M Hermann, H Sinzinger

  • 12nd Department of Nuclear Medicine, University of Vienna, Austria.

Prostaglandins, Leukotrienes, and Essential Fatty Acids
|August 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished.

Thrombosis research·1995
Same author

Passive smoking and cardiovascular risk.

Archives of internal medicine·1995
Same author

Gamma irradiation is not a novel approach to inhibit neointimal hyperplasia after arterial injury.

Stroke·1995
Same author

Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy.

Journal of cardiovascular pharmacology·1995
Same author

Evidence for lipid regression in humans in vivo performed by 123iodine-low-density lipoprotein scintiscanning.

Annals of the New York Academy of Sciences·1995
Same author

[1995 consensus guidelines for cholesterol. Society of Physicians in Vienna].

Wiener klinische Wochenschrift·1995
Same journal

Cardiovascular safety profile of prostaglandin E and prostacyclin analogues: Clinical reports and ex vivo studies on human coronary arteries.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same journal

Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same journal

Serum fatty acid distributions and prevalence of low omega-3 status in early pregnancy: A cross-sectional analysis of 26,389 samples from an omega-3 test-and-treat program.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same journal

Association of fish intake with systemic immune-inflammation index: Potential mediating role of n-3 polyunsaturated fatty acids.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same journal

A novel algae oil-based emulsion enhances chemotherapy outcome in human cancer models.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same journal

Human milk omega-3 PUFA and infant neurodevelopment: Evidence and insights from indian mothers.

Prostaglandins, leukotrienes, and essential fatty acids·2026
See all related articles

Prostaglandin I2 (PGI2) binding sites were identified in the human thyroid. Graves' disease patients showed significantly fewer PGI2 receptors, suggesting PGI2

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostaglandin I2 (PGI2) is a potent vasodilator and inhibitor of platelet aggregation.
  • The role of PGI2 in human thyroid function is not well understood.
  • Investigating PGI2-binding sites in the thyroid may reveal new insights into thyroid regulation.

Purpose of the Study:

  • To characterize prostaglandin I2 (PGI2)-binding sites in human thyroid tissue.
  • To compare PGI2 receptor density in euthyroid, thyrotoxic, and Graves' disease patients.
  • To elucidate the potential role of PGI2 in human thyroid function.

Main Methods:

  • Radioligand binding assays using 3H-iloprost, a stable PGI2 analogue.
  • Displacement studies with unlabeled iloprost, PGI2, and PGF2 alpha.

Related Experiment Videos

  • Scatchard analysis to determine binding site affinity and capacity.

    • Main Results:

    • Specific 3H-iloprost binding sites were identified in normal human thyroid tissue.
    • Scatchard analysis revealed high- and low-affinity binding sites.
    • Graves' disease thyroid tissue showed a significant decrease in PGI2 receptor density compared to normal thyroids.

    Conclusions:

    • The human thyroid gland possesses specific prostaglandin I2 (PGI2)-binding sites.
    • A significant reduction in PGI2 receptor density is observed in Graves' disease.
    • PGI2 may play a crucial role in regulating human thyroid function.